精神科医療の普及と教育に対するガイドラインの効果に関する研究
～Effectiveness of GUIdeline for Dissemination and Education in psychiatric treatment～
学術論文
Japanese Society of Neuropsychopharmacology. Japanese Society of Neuropsychopharmacology: "Guideline for pharmacological treatment of schizophrenia 2022".
Neuropsychopharmacol Rep,
DOI:10.1002/npr2.12497 (Epub ahead of print)
Ochi S, Tsuboi T, Hasegawa N, Hori H, Ichihashi K, Imamura Y, Okada T, Kodaka F, Saito Y, Iga J, Onitsuka T, Atake K, Ueno S, Hashimoto R, Yasui-Furukori N.
The association between benzodiazepine prescriptions and the risk of laxative use in schizophrenia treatment. Neuropsychopharmacol Rep,
DOI:10.1002/npr2.12499 (Epub ahead of print)
日本語の概要は こちら
Nakamura T, Furihata R, Hasegawa N, Kodaka F, Muraoka H, Ichihashi K, Ochi S, Numata S, Tsuboi T, Makinodan M, Iida H, Onitsuka T, Kashiwagi H, Takeshima M,
Hashimoto N, Nagasawa T, Usami M, Yamagata H, Takesu Y, Miura K, Matsumoto J, Ohi K, Yamada H, Hori H, Inada K, Watanabe K, Hashimoto R, Yasui-Furukori N.
The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior:
A multicenter study. BMC Psychiatry, 24, 399, 2024.5.
DOI: 10.1186/s12888-024-05816-x 日本語の概要は こちら
*Yamagata H, Fujii Y, Ochi S, Seki T, Hasegawa N, Yamada H, Hori H, Ichihashi K, Iga J, Ogasawara K, Hashimoto N, Iida H, Ohi K, Tsuboi T, Numata S, Hishimoto A,
Usami M, Katsumoto E, Muraoka H, Takaesu Y, Nagasawa T, Komatsu H, Miura K, Matsumoto J, Inada K, Nakagawqa S, Hashimoto R. Effect of the guideline education
program on anticholinergic and benzodiazepine use in outpatients with schizophrenia and major depressive disorder: The effectiveness of guidelines for
Dissemination and education in psychiatric treatment (EGUIDE) project. Psychiatry Research Communications, 4:100158, 2024.2
DOI: 10.1016/j.psycom.2024.100158 日本語の概要は こちら
Ito S, *Ohi K, Yasuda Y, Fujimoto J, Yamamori H, Matsumoto J, Fukumoto K, Kodaka F, Hasegawa N, Ishimaru K, Miura K, Yasui-Furukori N, Hashimoto R. Better adherence to
guidelines among psychiatrists providing pharmacological therapy is associated with longer work hours in patients with schizophrenia. Schizophrenia (Heidelb). 9(1):78, 2023.11
DOI: 10.1038/s41537-023-00407-3 日本語の概要は こちら
Hasegawa N, Yasuda Y, Yasui-Furukori N, Yamada H, Hori H, Ichihashi K, Takaesu Y, Iida H, Muraoka H, Kodaka F, Iga J, Hashimoto N, Ogasawara K, Ohi K,
Fukumoto K, Numata S, Tsuboi T, Usami M, Hishimoto A, Furihata R, Kishimoto T, Nakamura T, Katsumoto E, Ochi S, Nagasawa T, Atake K, Kubota C, Komatsu H,
Yamagata H, Ide K Takeshima M, Kido M, Kikuhchi S, Okada T, Matsumoto J, Miura K, Shimaza T, Inada K, Watanabe K, *Hashimoto R. Effect of education regarding
treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter study. Psychiatry Clin Neurosci, 77(10):559-568, 2023.10
DOI: 10.1111/pcn.13578 プレスリリースの内容は
こちら 日本語の概要は こちら
Kodaka F, *Ohi K, Yasuda Y, Fujimoto M, Yamamori H, Hasegawa N, Ito S, Fukumoto K, Matsumoto J, Miura K, Yasui-Furukori N, Hashimoto R. Relationships between
Adherence to Guideline Recommendations for Pharmacological Therapy among Clinicians and Psychotic Symptoms in Patients with Schizophrenia. Int J
Neuropsychopharmacol, 26(8):557-565, 2023.8
DOI: 10.1093/ijnp/pyad037 日本語の概要は こちら
Hashimoto N, *Yasui-Furukori N, Hasegawa N, Ishikawa S, Hori H, Iida H, Ichihashi K, Miura K, Matsumoto J, Numata S, Kodaka F,
Furihata R, Ohi K, Ogasawara K, Iga JI, Muraoka H, Komatsu H, Takeshima M, Atake K, Kido M, Nakamura T, Kishimoto T, Hishimoto A,
Onitsuka T, Okada T, Ochi S, Nagasawa T, Makinodan M, Yamada H, Tsuboi T, Yamada H, Inada K, Watanabe K, Hashimoto R.
Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing
surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project. BMC Psychiatry,
23(1):473, 2023.6
DOI: 10.1186/s12888-023-04908-4 日本語の概要は こちら
*Onitsuka T, Okada T, Hasegawa N, Tsuboi T, Iga J, Yaui-Furukori N, Yamada N, Hori H, Muraoka H, Ohi K, Ogasawara K,Ochi S,
Takeshima M, Ichihashi K, Fukumoto K, Iida H, Yamada H, Furihata R, Makinodan M, Takaesu Y, Numata S, Komatsu H, HIshimoto A,
Kido M, Atake K, Yamagata H, Kikuchi S, Hashimoto N, Usami M, Katsumoto E, Asami T, Kubota C, Matsumoto J, Miura K, Hirano Y,
Watanabe K, Inada K, Hashimoto R. Combination psychotropic use for schizophrenia with long-acting
injectable antipsychotics and oral antipsychotics: A nationwide real-world study in Japan. J Clin Psychopharmacol, 43(4):365-368, 2023.7/8
DOI: 10.1097/JCP.0000000000001704 日本語の概要は こちら
Iida H, Okada T, Nemoto K, Hasegawa N, Numata S, Ogasawara K, Miura K, Matsumoto J, Hori H, Iga J, Ichihashi K, Hashimoto N,
Yamada H, Ohi K, Yasui-Furukori N, Fukumoto K, Tsuboi T, Usami M, Furihata R, Takaesu Y, Hishimoto A, Muraoka H, Katsumoto E,
Nagasawa T, Ochi S, Komatsu H, Kikuchi S, Takeshima M, Onitsuka T, Tamai S, Kubota C, Inada K, Watanabe K, Kawasaki H, *Hashimoto R.
Satisfaction with Web-Based Courses on Clinical Practice Guidelines for Psychiatrists: Findings from the 'Effectiveness of Guidelines
for Dissemination and Education in Psychiatric Treatment (EGUIDE)' Project. Neuropsychopharmacol Rep, 43(1):23-32, 2023.3
DOI: 10.1002/npr2.12300 日本語の概要は こちら
Fukumoto K, Kodaka F, Hasegawa N, Muraoka H, Hori H, Ichihashi K, Yasuda Y, Iida H, Ohi K, Ochi S, Ide K, Hashimoto N, Usami M,
Nakamura T, Komatsu H, Okada T, Nagasawa T, Furihata R, Atake K, Kido M, Kikuchi S, Yamagata H, Kishimoto T, Makinodan M, Horai T,
Takeshima M, Kubota C, Asami T, Katsumoto E, Hishimoto A, Onitsuka T, Matsumoto J, Miura K, Yamada H, Yasui-Furukori N, Watanabe K,
Inada K, Otsuka K, *Hashimoto R. Development of an individual fitness score (IFS) based on the depression treatment guidelines of in
the Japanese Society of Mood Disorders. Neuropsychopharmacol Rep, 43(1):33-39, 2023.3
DOI: 10.1002/npr2.12301 日本語の概要は こちら
*Tsuboi T, Takaesu Y, Hasegawa N, Ochi S, Fukumoto K, Ohi K, Muraoka H, Okada T, Kodaka F, Igarashi S, Iida H, Kashiwagi H,
Hori H, Ichihashi K, Ogasawara K, Hashimoto N, Iga JI, Nakamura T, Usami M, Nagasawa T, Kido M, Komatsu H, Yamagata H, Atake K,
Furihata R, Kikuchi S, Horai T, Takeshima M, Hirano Y, Makinodan M, Matsumoto J, Miura K, Hishimoto A, Numata S, Yamada H,
Yasui-Furukori N, Inada K, Watanabe K, Hashimoto R. Effects of electroconvulsive therapy on the use of anxiolytics and sleep
medications: a propensity score-matched analysis. Psychiatry Clin Neurosci, 77(1):30-37, 2023.1
DOI: 10.1111/pcn.13489 日本語の概要は こちら
Kyou Y, *Yasui-Furukori N, Hasegawa N, Ide K, Ichihashi K, Hashimoto N, Hori H, Shimizu Y, Imamura Y, Muraoka H, Iida H, Ohi K,
Yasuda Y, Ogasawara K, Numata S, Iga JI, Tsuboi T, Ochi S, Kodaka F, Furihata R, Onitsuka T, Makinodan M, Komatsu H, Takeshima M,
Kubota C, Hishimoto A, Atake K, Yamagata H, Kido M, Nagasawa T, Usami M, Kishimoto T, Kikuchi S, Matsumoto J, Miura K, Yamada H,
Watanabe K, Inada K, Hahimoto R. The characteristics of discharge prescriptions including pro re nata psychotropic medications for
patients with schizophrenia and major depressive disorder from the survey of the "Effectiveness of guidelines for dissemination and
education in psychiatric treatment (EGUIDE)"project. Ann Gen Psychiatry, 21(1):52, 2022.12
DOI: 10.1186/s12991-022-00429-8 日本語の概要は こちら
Inada K, Fukumoto K, Hasegawa N, Yasuda Y, Yamada H, Hori H, Ichihashi K,Iida H, Ohi K, Muraoka H, Kodaka F, Ide K, Hashimoto N,
Iga JI, Ogasawara K, Atake K, Takaesu Y, Nagasawa T, Komatsu H, Okada T, Furihata R, Kido M, Kikuchi S, Kubota C, Makinodan M,
Ochi S, Takeshima M, Yamagata H, Matsumoto J, Miura K, Usami M, Kishimoto T, Onitsuka T, Katsumoto E, Hishimoto A, Numata S,
Yasui- Furukori N, Watanabe K, *Hashimoto R. Development of individual fitness score for conformity of prescriptions to the
"Guidelines For Pharmacological Therapy of Schizophrenia". Neuropsychopharmacol Rep. 42(4):502-509, 2022.12
DOI: 10.1002/npr2.12293 日本語の概要は こちら
Okada T, *Hori H, Hasegawa N, Murata A, Kyou Y, Kodaka F, Iida H, Ochi S, Takaesu Y, Tsuboi T, Iga JI, Ichihashi K, Muraoka H,
Furihata R, Yasui-Furukori N, Usami M, Onitsuka T, Ogasawara K, Tagata H, Takeshima M, Ohi K, Numata S, Hashimoto N, Yamada H,
Makinodan M, Komatsu H, Hishimoto A, Yamagata H, Kido M, Kubota C, Atake K, Yamada H, Nagasawa T, Matsumoto J, Miura K, Inada K,
Watanabe K, Suda S, Hashimoto R. Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic
Drugs in Hospitalized Patients With Schizophrenia. J Clin Psychopharmacol, 42(6):591-593, 2022.11
DOI: 10.1097/JCP.0000000000001604 日本語の概要は こちら
Ochi S, Tagata H, Hasegawa N, *Yasui-Furukori N, Iga JI, Kashiwagi H, Kodaka F, Komatsu H, Tsuboi T, Tokutani A, Numata S,
Ichihashi K, Onitsuka T, Muraoka H, Iida H, Ohi K, Atake K, Kishimoto T, Hori H, Takaesu Y, Takeshima M, Usami M, Makinodan M,
Hashimoto N, Fujimoto M, Furihata R, Nagasawa T, Yamada H, Matsumoto J, Miura K, Kido M, Hishimoto A, Ueno SI, Watanabe K,
Inada K, Hashimoto R. Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower
Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study.
Int J Neuropsychopharmacol, 25(10):818-826, 2022.10
DOI: 10.1093/ijnp/pyac036 日本語の概要は こちら
Muraoka H, Kodaka F, Hasegawa N, *Yasui-Furukori N, Fukumoto K, Kashiwagi H, Tagata H, Hori H, Atake K, Iida H, Ichihashi K, Furihata R,
Tsuboi T, Takeshima M, Komatsu H, Kubota C, Ochi S, Takaesu Y, Usami M, Nagasawa T, Makinodan M, Nakamura T, Kido M, Ueda I, Yamagata H,
Onitsuka T, Asami T, Hishimoto A, Ogasawara K, Katsumoto E, Miura K, Matsumoto J, Ohi K, Yamada H, Watanabe K, Inada K, Nishimura K,
Hashimoto R. Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site study.
Asian J Psychiatr, 74:103174, 2022.8
DOI: 10.1016/j.ajp.2022.103174 日本語の概要は こちら
*Hori H, Yasui-Furukori N, Hasegawa N, Iga J, Ochi S, Ichihashi K,
Furihata R, Kyo Y, Takaesu Y, Tsuboi T, Kodaka F, Onitsuka T,
Okada T, Murata A, Kashiwagi H, Iida H, Hashimoto N, Ohi K,
Yamada H, Ogasawara K, Yasuda Y, Muraoka H, Usami M, Numata S,
Takeshima M, Yamagata H, Nagasawa T, Tagata H, Makinodan M,
Kido M, Katsumoto E, Komatsu H, Matsumoto J, Kubota C, Miura K,
Hishimoto A, Watanabe K, Inada K, Kawasaki H, Hashimot R.
Prescription of anticholinergic drugs in patients with
schizophrenia: analysis of antipsychotic prescription patterns
and hospital characteristics.
Front Psychiatry, section Psychopharmacology, 13:823826, 2022.5
DOI: 10.3389/fpsyt.2022.823826 日本語の概要は こちら
Yamada H, Motoyama M, Hasegawa N, Miura K, Matsumoto J, Ohi K,
Yasui-Furukori N, Numata S, Takeshima M, Sugiyama N, Nagasawa T,
Kubota C, Atake K, Tsuboi T, Ichihashi K, Hashimoto N, Inagaki T,
Takaesu Y, Iga JI, Hori H, Onitsuka T, Komatsu H, Hishimoto A,
Fukumoto K, Fujimoto M, Nakamura T, Nemoto K, Furihata R,
Yamamura S, Yamagata H, Ogasawara K, Katsumoto E, Murata A,
Iida H, Ochi S, Makinodan M, Kido M, Kishimoto T, Yasuda Y,
Usami M, Suwa T, Inada K, Watanabe K, *Hashimoto R.
A dissemination and education programme to improve the clinical
behaviours of psychiatrists in accordance with treatment
guidelines for schizophrenia and major depressive disorders:
the Effectiveness of Guidelines for Dissemination and Education
in Psychiatric Treatment (EGUIDE) project.
BJPsych Open, 8(3):e83, 2022.4
DOI: 10.1192/bjo.2022.44 日本語の概要は こちら
Ogasawara K, Numata S, Hasegawa N, Nakataki M, Makinodan M, Ohi K,
Takeshima M, Tsuboi T, Hashimoto N, Onitsuka T, Muraoka H, Hori H,
Ichihashi K, Inagaki T, Yasui-Furukori N, Hishimoto A, Sugiyama N,
Fukumoto K, Nagasawa T, Matsumoto J,Takaesu Y, Furihata R, Nemoto K,
Nakamura T, Usami M, Miura K, Fujimoto M,Tagata H, Yamada H, Komatsu H,
Ochi S, Atake K, Katsumoto E, Kido M, Kishimoto T, Suwa T,
Yamamura S, Iga JI, Iida H, Inada K, Watanabe K, *Hashimoto R.
Subjective assessment of participants in education programs on
clinical practice guidelines in the field of psychiatry.
Neuropsychopharmacol Rep, 42(2): 221-225, 2022.6
DOI: 10.1002/npr2.12245 日本語の概要は こちら
Ichihashi K, Kyou Y, Hasegawa N, Yasui-Furukori N, Shimnizu Y, Hori H, Hashimoto N, Ide K, Imamura Y, Yamada H, Ochi S, Iga J, Takaesu Y,
Ohi K, Tsuboi T, Iida H, Yamagata H, Hishimoto A, Horai T, Usami M, Makinodan M, Nagasawa T, Komatsu H, Kido M, Muraoka H, Atake K,
Takeshima M, Kubota C, Inagaki T, Tamai S, Kishimoto T, Furihata R, Matsumoto J, Miura K, Inada K, Watanabe K, Kasai K, *Hashimoto R.
The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major
depressive disorder: A nationwide survey from the EGUIDE project. Asian J Psychiatr, 69:103007, 2022.3
DOI:10.1016/j.ajp.2022.103007 日本語の概要は こちら
Yasui-Furukori N, Muraoka H, Hasegawa N, Ochi S, Numata S, Hori H, Hishimoto A, Onitsuka T, Ohi K, Hashimoto N, Nagasawa T, Takaesu Y,
Inagaki T, Tagata H, Tsuboi T, Kubota C, Furihata R, Iga J, Iida H, Miura K, Matsumoto J, Yamada H, Watanabe K, Inada K, Shimoda K,
*Hashimoto R. Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a
nationwide dissemination and implementation study. Neuropsychopharmacol Rep, 42(1):3-9, 2022.3
DOI:10.1002/npr2.12218
プレスリリースの内容はこちら
Furihata R, Otsuki R, Hasegawa N, Tsuboi T, Numata S, Yasui-Furukori N, Kashiwagi H, Hori H, Ochi S, Muraoka H, Onitsuka T, Komatsu H,
Takeshima M, Hishimoto A, Nagasawa T, Takaesu Y, Nakamura T, Asami T, Miura K, Matsumoto J, Ohi K, Yasuda Y, Iida H, Ogasawara K,
Hashimoto N, Ichihashi K, Yamada H, Watanabe K, Inada K, *Hashimoto R. Hypnotic medication use among inpatients with schizophrenia and
major depressive disorder: results of a nationwide study. Sleep Med, 89:23-30, 2021.12
DOI:10.1016/j.sleep.2021.11.005 日本語の概要は こちら
Japanese Society of Neuropsychopharmacology. Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of
Schizophrenia". Neuropsychopharmacol Rep, 41(3):266-324, 2021.9
DOI:10.1002/npr2.12193
Hashimoto N,*Yasui-Furukori N, Hasegawa N, Ishikawa S, Numata S, Hori H, Iida H, Ichihashi K, Furihata R, Murata A, Tsuboi T,
Takeshima M, Kyou Y, Komatsu H, Kubota C, Ochi S, Takaesu Y, Usami M, Nagasawa T, Hishimoto A, Miura K, Matsumoto J, Ohi K, Yamada H,
Inada K, Watanabe K, Shimoda K, Hashimoto R. Characteristics of discharge prescriptions for patients with schizophrenia or major depressive
disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project.
Asian Journal of Psychiatry, 63:102744, 2021.7 DOI:10.1016/j.ajp.2021.102744 日本語の概要は こちら
Numata S, Nakataki M, Hasegawa N, Takaesu Y, Takeshima M, Onitsuka T, Nakamura T, Edagawa R, Edo H, Miura K, Matsumoto J,
Yasui-Furukori N, Kishimoto T, Hori H, Tsuboi T, Yasuda Y, Furihata R, Muraoka H, Ochi S, Nagasawa T, Kyou Y, Murata A, Katsumoto E,
Ohi K, Hishimoto A, Inada K, Watanabe K, *Hashimoto R. Improvements in the degree of understanding the treatment guidelines for
schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep,
41(2):199-206, 2021.6 DOI:10.1002/npr2.12173 日本語の概要はこちら
Iida H, Iga J, Hasegawa N, Yasuda Y, Yamamoto T, Miura K, Matsumoto J, Murata A,
Ogasawara K, Yamada H, Hori H, Ichihashi K, Hashimoto N, Ohi K, Yasui-Furukori N, Tsuboi T, Nakamura T, Usami M, Furihata R, Takaesu Y,
Iwamoto K, Sugiyama N, Kishimoto T, Tsujino N, Yamada H, Hishimoto A, Nemoto K, Atake K, Muraoka H, Katsumoto E, Oishi S, Inagaki T,
Ito F, Imamura Y, Kido M, Nagasawa T, Numata S, Ochi S, Iwata M, Yamamori H, Fujita J, Onitsuka T, Yamamura S, Makinodan M, Fujimoto M,
Takayanagi Y, Takezawa K, Komatsu H, Fukumoto K, Tamai S, Yamagata H, Kubota C, Horai T, Inada K, Watanabe K, Kawasaki H,
*Hashimoto R. Unmet need for major depressive disorders-Findings from the ‘Effectiveness of Guidelines for Dissemination
and Education in Psychiatric Treatment (EGUIDE)’ project: A nationwide dissemination, education, and evaluation study. Psychiatry Clin
Neurosci,74(12):667-669, 2020.12 DOI:10.1111/pcn. 13143 日本語の概要は
こちら
Ichihashi K, Hori H, Hasegawa N, Yasuda Y, Yamamoto T, Tsuboi T, Iwamoto K, Kishimoto T, Horai T, Yamada H, Sugiyama N,
Nakamura T, Tsujino N, Nemoto K, Oishi S, Usami M, Katsumoto E, Yamamori H, Tomita H, Suwa T, Furihata R, Inagaki T, Fujita J, Onitsuka T,
Miura K, Matsumoto J, Ohi K, Matsui Y, Takaesu Y, Hashimoto N, Iga J, Ogasawara K, Yamada H, Watanabe K,
Inada K, *Hashimoto R. Prescription patterns in patients with schizophrenia in Japan: first-quality indicator data from the
survey of “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)” project. Neuropsychopharmacol
Rep, 40(3):281-286, 2020.9 DOI:10.1002/npr2.12122 日本語の概要はこちら →NPPR Article Award 2021を受賞しました。（詳細はこちら）
Takaesu Y, Watanabe K, Numata S, Iwata M, Kudo N, Oishi S, Takizawa T, Nemoto K, Yasuda Y, Tagata H, Tsuboi T, Tsujino N, Hashimoto N,
Matsui Y, Hori H, Yamamori H, Sugiyama N, Suwa T, Kishimoto T, Hishimoto A, Usami M, Furihata R, Iwamoto K, Fujishiro H, Nakamura T,
Mizuno K, Inagaki T, Katsumoto E, Tomita H, Ohi K, Muraoka H, Atake K, Iida H, Nagasawa T, Fujita J, Yamamura S, Onitsuka T, Murata A,
Takayanagi Y, Noda H, Matsumura Y, Takezawa K, Iga J, Ichihashi K, Ogasawara K, Yamada H, Inada K, *Hashimoto R.
Improvement of psychiatrists’ clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the
“Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE) ” project: a nationwide dissemination,
education and evaluation study. Psychiatry Clin Neurosci, 73(10):642-648, 2019.10
DOI:10.1111/pcn.12911 プレスリリースの内容は
こちら
